Published in BMJ on March 23, 2010
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. J Clin Oncol (2015) 3.19
Breast cancer mortality trends in England and the assessment of the effectiveness of mammography screening: population-based study. J R Soc Med (2013) 2.20
Modern mammography screening and breast cancer mortality: population study. BMJ (2014) 1.92
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer (2013) 1.42
Citations of scientific results and conflicts of interest: the case of mammography screening. Evid Based Med (2013) 1.42
Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer (2011) 1.22
Benefits and harms of mammography screening. Breast Cancer Res (2015) 1.22
Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Cancer Res (2012) 1.19
Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res (2012) 1.16
Mammography Screening: Evidence, History and Current Practice in Germany and Other European Countries. Breast Care (Basel) (2011) 1.10
The breast screening programme and misinforming the public. J R Soc Med (2011) 1.09
Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol (2014) 1.09
Breast cancer screening: evidence of benefit depends on the method used. BMC Med (2012) 1.04
Breast cancer screening: are we seeing the benefit? BMC Med (2012) 1.02
Time to stop mammography screening? CMAJ (2011) 1.02
An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer (2011) 0.99
Beyond the mammography debate: a moderate perspective. Curr Oncol (2015) 0.97
Mammography Screening - as of 2013. Geburtshilfe Frauenheilkd (2013) 0.95
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Breast cancer in European Union: an update of screening programmes as of March 2014 (review). Int J Oncol (2014) 0.88
Explaining variations in breast cancer screening across European countries. Eur J Health Econ (2013) 0.88
Screening mammography & breast cancer mortality: meta-analysis of quasi-experimental studies. PLoS One (2014) 0.87
Population-based screening for colorectal cancer with faecal occult blood test--do we really have enough evidence? Int J Colorectal Dis (2010) 0.85
Flawed methods explain the effect of mammography screening in Nijmegen. Br J Cancer (2011) 0.84
A cross-sectional study on informed choice in the mammography screening programme in Germany (InEMa): a study protocol. BMJ Open (2014) 0.84
Contribution of early detection and adjuvant treatments to breast cancer mortality reduction in Catalonia, Spain. PLoS One (2012) 0.82
Risk analysis: A dense issue. Nature (2012) 0.82
Population-based service mammography screening: the Icelandic experience. Breast Cancer (Dove Med Press) (2013) 0.81
Rational and irrational issues in breast cancer screening. Cancers (Basel) (2011) 0.80
Is the tide turning against breast screening? Breast Cancer Res (2012) 0.80
Non-attendance of mammographic screening: the roles of age and municipality in a population-based Swedish sample. Int J Equity Health (2015) 0.79
The impact of the Polish mass breast cancer screening program on prognosis in the Pomeranian Province. Arch Med Sci (2016) 0.77
Women's participation in breast cancer screening in France--an ethical approach. BMC Med Ethics (2014) 0.77
Mammography interval and breast cancer mortality in women over the age of 75. Breast Cancer Res Treat (2014) 0.77
Viewpoint: It is time to reconsider policy for population-based mammography screening. J Public Health Policy (2015) 0.75
Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening. PLoS One (2016) 0.75
Screening, case finding or primary cancer prevention in the developing world? Eur J Epidemiol (2013) 0.75
Frank words about breast screening. Open Med (2011) 0.75
Mammographic screening for breast cancer: A review. J Med Radiat Sci (2013) 0.75
[Breast cancer mortality in organised mammography screening in Denmark]. Praxis (Bern 1994) (2010) 0.75
Breast Cancer Screening Programmes across the WHO European Region: Differences among Countries Based on National Income Level. Int J Environ Res Public Health (2017) 0.75
Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline. BMC Cancer (2014) 0.75
Health beliefs as predictors of breast cancer screening behaviour in a group of female employees in shiraz. Iran J Cancer Prev (2012) 0.75
The global challenge of reducing breast cancer mortality. Oncologist (2013) 0.75
Benefit-to-harm ratio of the Danish breast cancer screening programme. Int J Cancer (2017) 0.75
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 12.65
Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med (1980) 5.23
Screening for breast cancer with mammography. Cochrane Database Syst Rev (2006) 5.19
Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ (2005) 3.21
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (2002) 2.85
Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev (2006) 2.53
UK deaths from breast cancer fall to lowest figure for 40 years. BMJ (2009) 1.77
Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev (2005) 1.50
Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health (2009) 1.35
Estimating the benefits of mammography screening: the impact of study design. Epidemiology (2007) 1.32
Do nonattenders in mammography screening programmes seek mammography elsewhere? Int J Cancer (2005) 1.15
Women's patterns of participation in mammography screening in Denmark. Eur J Epidemiol (2006) 1.11
Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat (2008) 1.11
Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol (2005) 1.11
Screening and breast cancer. N Engl J Med (2006) 0.95
Fall in breast cancer deaths. A cause for celebration, and caution. BMJ (2009) 0.95
Reduction in mortality from breast cancer: decrease with screening was marked in younger age group. BMJ (2005) 0.92
Reduction in mortality from breast cancer: presentation of benefits and harms needs to be balanced. BMJ (2005) 0.89
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA (2004) 23.87
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med (2004) 11.47
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ (2009) 8.31
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev (2012) 6.15
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ (2006) 4.42
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
Opening up data at the European Medicines Agency. BMJ (2011) 3.96
Content of invitations for publicly funded screening mammography. BMJ (2006) 3.71
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ (2010) 3.46
Placebo interventions for all clinical conditions. Cochrane Database Syst Rev (2010) 3.45
Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol (2008) 3.11
Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ (2004) 3.07
General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ (2012) 3.03
What is publication? Lancet (2006) 3.02
Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. J Clin Psychol (2007) 2.92
Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ (2005) 2.80
Does long term use of psychiatric drugs cause more harm than good? BMJ (2015) 2.76
Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA (2002) 2.58
Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ (2008) 2.56
Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol (2011) 2.45
Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med (2010) 2.24
What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction (2012) 2.22
Should journals stop publishing research funded by the drug industry? BMJ (2014) 2.13
The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepatobiliary randomized clinical trials. Am J Gastroenterol (2005) 2.12
[Should the announcement of scientific dishonesty be revised yet again?]. Ugeskr Laeger (2013) 2.01
Our prescription drugs kill us in large numbers. Pol Arch Med Wewn (2014) 2.00
[New cancer drugs are no better than old]. Ugeskr Laeger (2013) 1.95
[Overinterpretation of a non-conclusive population study on breast cancer]. Ugeskr Laeger (2004) 1.94
[Are invitations to mammography screening a reasonable basis for informed consent?-- Secondary publication]. Ugeskr Laeger (2006) 1.92
[The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. Gac Sanit (2008) 1.87
Constraints on publication rights in industry-initiated clinical trials. JAMA (2006) 1.82
Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology (2011) 1.76
General health checks in adults for reducing morbidity and mortality from disease. JAMA (2013) 1.70
Universal health checks should be abandoned. BMJ (2013) 1.67
Registries and registration of clinical trials. N Engl J Med (2005) 1.48
Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol (2009) 1.46
Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. BMC Med (2007) 1.43
Citations of scientific results and conflicts of interest: the case of mammography screening. Evid Based Med (2013) 1.42
Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control (2011) 1.41
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA (2006) 1.40
[Dubious documentation of the effect of acupuncture]. Ugeskr Laeger (2006) 1.39
[Transparency, reliability and conflict of interest]. Ugeskr Laeger (2011) 1.39
[Screening for obsessive thoughts, depression and ADDH?]. Ugeskr Laeger (2013) 1.39
What do we know about the safety of the HPV vaccines? Tidsskr Nor Laegeforen (2017) 1.39
[Information about breast cancer screening presented on websites is biased and insufficient--a secondary publication]. Ugeskr Laeger (2005) 1.38
Norwegian mammography screening - numerous self-contradictions in the evaluation. Tidsskr Nor Laegeforen (2016) 1.38
PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med (2013) 1.36
Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health (2009) 1.35
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. Rev Esp Salud Publica (2008) 1.35
Access to data in industry-sponsored trials. Lancet (2011) 1.28
Biases in estimates of overdetection due to mammography screening. Lancet Oncol (2008) 1.24
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMC Med Res Methodol (2008) 1.24
Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. J Clin Epidemiol (2009) 1.21
Spontaneous regression of cancerous tumors detected by mammography screening. JAMA (2004) 1.20
Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics (2013) 1.19
The benefits and harms of screening for cancer with a focus on breast screening. Pol Arch Med Wewn (2010) 1.17
Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol (2008) 1.17
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol (2004) 1.13
[In Process Citation]. Ugeskr Laeger (2015) 1.07
Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (2013) 1.07
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit (2009) 1.05
Influence of mammography screening on use of mastectomies in Denmark. Acta Oncol (2014) 1.05
Sponsors' participation in conduct and reporting of industry trials: a descriptive study. Trials (2012) 1.04
Effect of screening mammography on breast cancer incidence. N Engl J Med (2013) 1.04
Who evaluates public health programmes? A review of the NHS Breast Screening Programme. J R Soc Med (2010) 1.02
Social inequalities in mortality: changes in the relative importance of income, education and household size over a 27-year period. Eur J Public Health (2005) 1.01
A decline in breast-cancer incidence. N Engl J Med (2007) 1.01
An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer (2011) 0.99
Challenges in coding adverse events in clinical trials: a systematic review. PLoS One (2012) 0.98
Is birth history the key to highly educated women's higher breast cancer mortality? A follow-up study of 500,000 women aged 35-54. Int J Cancer (2005) 0.98
Physical activity for secondary prevention of disease. Systematic reviews of randomised clinical trials. Dan Med Bull (2005) 0.96
Screening for breast cancer. Ann Intern Med (2003) 0.96
Fall in breast cancer deaths. A cause for celebration, and caution. BMJ (2009) 0.95